Advances in Treatment of Lung Cancer With Targeted Therapy

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor

(2011) Ahad A. Sadiq et al.   Journal of Thoracic Oncology

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

(2010) Elisa Benedettini et al.   AMERICAN JOURNAL OF PATHOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers

(2009) L. M. Sholl et al.   CANCER RESEARCH

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

(2009) Takeshi Yoshida et al.   CANCER SCIENCE

Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer

(2009) Howard West et al.   CHEST

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer

(2009) J. Yu et al.   CLINICAL CANCER RESEARCH

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Lung Cancer Trials Probe Effects of Maintenance Therapy, Targeted Agents

(2009) Tracy Hampton   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2009) Tony S.K. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

(2008) Noriko Motoi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Clinical significance of TTF-1 protein expression andTTF-1gene amplification in lung adenocarcinoma

(2008) Justine A. Barletta et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

(2008) Vincent A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA